GlassScriptPhysician profile
Candace NP Cassady
NPI 1093922718
$7,757.06
in general payments reported to CMS, 2019-2025
44 companies · $2,376 in 2025
The $2,376 reported for 2025 was more than what 95% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $57.15 · 2022: $990 · 2023: $2,157 · 2024: $2,177 · 2025: $2,376.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,995 · Education: $715.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,995.11 |
| Education | $714.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $805.98 | 2023-2025 | Jakafi, Jakafi, Monjuvi |
| Merck Sharp & Dohme LLC | $751.82 | 2022-2025 | Keytruda, Lynparza, Welireg |
| Novartis Pharmaceuticals Corporation | $727.02 | 2021-2025 | |
| Astellas Pharma US INC | $604.61 | 2022-2025 | Xtandi, Padcev, Xospata |
| Genentech USA, INC. | $423.21 | 2023-2025 | Polivy, Tecentriq, Columvi |
| Astrazeneca Pharmaceuticals LP | $355.45 | 2022-2025 | Imfinzi, Lynparza, Calquence |
| Celgene Corporation | $332.78 | 2021-2025 | Reblozyl, Pomalyst |
| Regeneron Healthcare Solutions, INC. | $332.19 | 2022-2025 | Libtayo |
| E.R. Squibb & Sons, L.L.C. | $325.54 | 2022-2025 | Opdivo, Opdualag, Krazati |
| Stemline Therapeutics INC. | $284.86 | 2024-2025 | Orserdu |
| Pfizer INC. | $218.52 | 2023-2025 | |
| Amgen INC. | $211.15 | 2021-2025 | Imdelltra (Amg757) |
| Eisai INC. | $207.74 | 2022-2025 | |
| Dendreon Pharmaceuticals LLC | $197.19 | 2023-2025 | Provenge |
| Bayer Healthcare Pharmaceuticals INC. | $148.43 | 2023-2025 |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $139.56 | 2022-2025 | Ojjaara, Blenrep |
| Genzyme Corporation | $138.62 | 2022-2025 | |
| Daiichi Sankyo INC. | $135.27 | 2024-2025 | Enhertu, Datroway |
| Array Biopharma INC | $130.46 | 2023-2025 | Braftovi, Mektovi, Lorbrena |
| Gilead Sciences, INC. | $123.69 | 2023-2025 | Trodelvy |
| Janssen Biotech, INC. | $118.21 | 2024-2025 | Erleada, Akeega, Balversa |
| Myriad Genetic Laboratories, INC. | $117.08 | 2023-2024 | Bracanalysis Cdx, Precisetumor |
| Epizyme, INC. | $99.95 | 2022 | |
| Sanofi-Aventis U.S. LLC | $85.95 | 2022 | |
| Seagen INC. | $78.93 | 2022-2023 | Adcetris, Tukysa |
| Janssen Scientific Affairs, LLC | $73.97 | 2022-2024 | Darzalex, Talvey, Tecvayli |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.85 | 2025 | |
| Aveo Pharmaceuticals, INC. | $54.69 | 2024-2025 | |
| Beigene USA, INC. | $51.14 | 2022-2025 | Brukinsa |
| Emd Serono, INC. | $49.28 | 2023-2025 | Bavencio |
| Pharmacosmos Therapeutics INC. | $46.80 | 2023-2024 | Monoferric |
| Beone Medicines USA, INC. | $44.70 | 2025 | Brukinsa |
| Puma Biotechnology, INC. | $38.92 | 2024-2025 | |
| Blueprint Medicines Corporation | $38.51 | 2023 | Ayvakit |
| Karyopharm Therapeutics INC. | $30.08 | 2022 | |
| Genmab U.S., INC. | $25.35 | 2025 | Epkinly |
| Jazz Pharmaceuticals INC. | $22.87 | 2022 | |
| Deciphera Pharmaceuticals INC. | $21.69 | 2025 | Qinlock, Romvimza |
| Takeda Pharmaceuticals U.S.A., INC. | $19.82 | 2024 | Fruzaqla |
| Spectrum Pharmaceuticals INC. | $18.88 | 2025 | Rolvedon |
| Sumitomo Pharma America, INC. | $17.64 | 2024 | Orgovyx |
| Taiho Oncology, INC. | $17.00 | 2024 | |
| Adaptive Biotechnologies Corporation | $13.91 | 2024 | Clonoseq |
| Alexion Pharmaceuticals, INC. | $13.75 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Candace Cassady listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.